Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Microbiology and Molecular Genetics: Razin Shmuel


 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Banerjee S, Sionov RV, Feldman M, Smoum R, Mechoulam R, Steinberg D. Anandamide alters the membrane properties, halts the cell division and prevents drug efflux in multidrug resistant Staphylococcus aureus. Sci Rep 2021;11(1).

(2) Kogan NM, Peters M, Mechoulam R. Cannabinoid Quinones-A Review and Novel Observations. Molecules 2021;26(6).

(3) Rock EM, Limebeer CL, Sullivan MT, DeVuono MV, Lichtman AH, Di Marzo V, et al. N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. Front Synaptic Neurosci 2021;13.

(4) Feldman M, Sionov RV, Mechoulam R, Steinberg D. Anti-biofilm activity of cannabidiol against candida albicans. Microorg 2021;9(2):1-17.

(5) Di Bartolomeo M, Stark T, Maurel OM, Iannotti FA, Kuchar M, Ruda-Kucerova J, et al. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacol Res 2021;164.

(6) Mechoulam R. Foreword. Adv Exp Med Biol 2021;1297:ix-xi.

(7) Mechoulam R. Foreword. Adv Exp Med Biol 2021;1264:ix-xi.

(8) Sionov RV, Feldman M, Smoum R, Mechoulam R, Steinberg D. Anandamide prevents the adhesion of filamentous Candida albicans to cervical epithelial cells. Sci Rep 2020;10(1).

(9) Rock EM, Sullivan MT, Collins SA, Goodman H, Limebeer CL, Mechoulam R, et al. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. Psychopharmacology 2020;237(9):2621-2631.

(10) Ayoub SM, Smoum R, Farag M, Atwal H, Collins SA, Rock EM, et al. Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. Psychopharmacology 2020;237(9):2753-2765.

(11) Stark T, Di Bartolomeo M, Di Marco R, Drazanova E, Platania CBM, Iannotti FA, et al. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochem Pharmacol 2020;177.

(12) Zhu YF, Linher-Melville K, Niazmand MJ, Sharma M, Shahid A, Zhu KL, et al. An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain. Br J Pharmacol 2020;177(12):2712-2725.

(13) Piscitelli F, Guida F, Luongo L, Iannotti FA, Boccella S, Verde R, et al. Protective Effects of N-Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. ACS Chem Neurosci 2020;11(8):1117-1128.

(14) Feldman M, Smoum R, Mechoulam R, Steinberg D. Potential combinations of endocannabinoid/ endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus. PLoS ONE 2020;15(4).

(15) Murillo-Rodríguez E, Arankowsky-Sandoval G, Pertwee RG, Parker L, Mechoulam R. Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats. Brain Res Bull 2020;155:166-173.

(16) Rock EM, Ayoub SM, Limebeer CL, Gene A, Wills KL, DeVuono MV, et al. Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. Psychopharmacology 2020;237(2):375-384.

(17) Pacher P, Kogan NM, Mechoulam R. Beyond THC and endocannabinoids. Annu Rev Pharmacol Toxicol 2020;60:637-659.

(18) Feldman M, Sionov R, Smoum R, Mechoulam R, Ginsburg I, Steinberg D. Comparative Evaluation of Combinatory Interaction between Endocannabinoid System Compounds and Poly-L-lysine against Streptococcus mutans Growth and Biofilm Formation. BioMed Res Int 2020;2020.

(19) Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep 2019;9(1).

(20) Baraghithy S, Smoum R, Attar-Namdar M, Mechoulam R, Bab I, Tam J. Hu-671, a novel oleoyl serine derivative, exhibits enhanced efficacy in reversing ovariectomy-induced osteoporosis and bone marrow adiposity. Molecules 2019;24(20).

(21) Petrie GN, Wills KL, Piscitelli F, Smoum R, Limebeer CL, Rock EM, et al. Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats. Psychopharmacology 2019;236(9):2623-2633.

(22) Friedman L, Smoum R, Feldman M, Mechoulam R, Steinberg D. Does the Endocannabinoid Anandamide Affect Bacterial Quorum Sensing, Vitality, and Motility? Cannabis and Cannabinoid Res 2019;4(2):102-109.

(23) Magid L, Heymann S, Elgali M, Avram L, Cohen Y, Liraz-Zaltsman S, et al. Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury. J Neurotrauma 2019;36(11):1836-1846.

(24) Donvito G, Piscitelli F, Muldoon P, Jackson A, Vitale RM, D'Aniello E, et al. N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology 2019;148:320-331.

(25) Shbiro L, Hen-Shoval D, Hazut N, Rapps K, Dar S, Zalsman G, et al. Effects of cannabidiol in males and females in two different rat models of depression. Physiol Behav 2019;201:59-63.

(26) Stark T, Ruda-Kucerova J, Iannotti FA, D'Addario C, Di Marco R, Pekarik V, et al. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology 2019;146:212-221.

(27) Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R. Cannabidiol partially blocks the excessive sleepiness in hypocretin-deficient rats: Preliminary data. CNS Neurol Disord Drug Targets 2019;18(9):705-712.

(28) Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Rev Bras Psiquiatr 2019;41(1):9-14.

(29) Baraghithy S, Smoum R, Drori A, Hadar R, Gammal A, Hirsch S, et al. Magel2 Modulates Bone Remodeling and Mass in Prader-Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. J Bone Miner Res 2019;34(1):93-105.

(30) Feldman M, Smoum R, Mechoulam R, Steinberg D. Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. Sci Rep 2018;8(1).

(31) Chiurchiù V, Leuti A, Smoum R, Mechoulam R, Maccarrone M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J 2018;32(10):5716-5723.

(32) Hen-Shoval D, Amar S, Shbiro L, Smoum R, Haj CG, Mechoulam R, et al. Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. Behav Brain Res 2018;351:1-3.

(33) Abuhasira R, Schleider LB-, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 2018;49:44-50.

(34) Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 2018;49:37-43.

(35) Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. Br J Pharmacol 2018;175(1):100-112.

(36) Večeřa J, Bártová E, Krejčí J, Legartová S, Komůrková D, Rudá-Kučerová J, et al. HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals. J Cell Physiol 2018;233(1):530-548.

(37) Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, et al. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep 2017;7(1).

(38) Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM, et al. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Prog Neuro-Psychopharmacol Biol Psychiatry 2017;79:369-377.

(39) Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA. Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology 2017;234(14):2207-2217.

(40) Mechoulam R. Foreword. Cannabis sativa L - Bot and Biotechnol 2017:vii-viii.

(41) Mechoulam R. Cannabis and epilepsy. Epilepsy Behav 2017;70:278-279.

(42) Rock EM, Boulet N, Limebeer CL, Mechoulam R, Parker LA. Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. Eur J Pharmacol 2016;786:94-99.

(43) Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, et al. Correction: Fluorinated cannabidiol derivatives: Enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects (PLoS ONE (2016) 11:7 (e0158779) DOI: 10.1371/journal.pone.0158779). PLoS ONE 2016;11(8).

(44) Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, et al. Fluorinated cannabidiol derivatives: Enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLoS ONE 2016;11(7).

(45) Mechoulam R. Cannabis - The Israeli perspective. J Basic Clin Physiol Pharmacol 2016;27(3):181-187.

(46) Juknat A, Kozela E, Kaushansky N, Mechoulam R, Vogel Z. Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - Studies in BV-2 microglia and encephalitogenic T cells. J Basic Clin Physiol Pharmacol 2016;27(3):289-296.

(47) Mann A, Cohen-Yeshurun A, Trembovler V, Mechoulam R, Shohami E. Are the endocannabinoid-like compounds N-acyl aminoacids neuroprotective after traumatic brain injury? J Basic Clin Physiol Pharmacol 2016;27(3):209-216.

(48) Maslov LN, Khaliulin I, Zhang Y, Krylatov AV, Naryzhnaya NV, Mechoulam R, et al. Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists. J Cardiovasc Pharmacol Ther 2016;21(3):262-272.

(49) Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, et al. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology 2016;73(2):123-129.

(50) Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, et al. HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chem Biol Drug Des 2016;87(1):143-153.

(51) Lee W-, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, et al. Cannabidiol limits T cell–mediated chronic autoimmune myocarditis: Implications to autoimmune disorders and organ transplantation. Mol Med 2016;22:136-146.

(52) Fisher T, Golan H, Schiby G, Prichen S, Smoum R, Moshe I, et al. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 2016;23:S15-S22.

(53) Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, et al. HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J Pharmacol Exp Ther 2015;355(1):66-75.

(54) Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, et al. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biol Blood Marrow Transplant 2015;21(10):1770-1775.

(55) Mechoulam R. Preface. Endocannabinoids 2015:vii-ix.

(56) Soni D, Smoum R, Breuer A, Mechoulam R, Steinberg D. Effect of the synthetic cannabinoid HU-210 on quorum sensing and on the production of quorum sensing-mediated virulence factors by Vibrio harveyi. BMC Microbiol 2015;15(1).

(57) Smoum R, Baraghithy S, Chourasia M, Breuer A, Mussai N, Attar-Namdar M, et al. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. Proc Natl Acad Sci U S A 2015;112(28):8774-8779.

(58) Mann A, Smoum R, Trembovler V, Alexandrovich A, Breuer A, Mechoulam R, et al. Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury. J Neuroimmune Pharmacol 2015;10(2):356-363.

(59) Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 2015;36(5):277-296.

(60) Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, et al. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med 2015;21:38-45.

(61) Mechoulam R. The Endocannabinoid System: A Look Back and Ahead. Handb Exp Pharmacol 2015;231:vii-ix.

(62) Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2015;203:75-104.

(63) Sticht MA, Jacklin DL, Mechoulam R, Parker LA, Winters BD. Intraperirhinal cortex administration of the synthetic cannabinoid, HU210, disrupts object recognition memory in rats. Neuroreport 2015;26(5):258-262.

(64) Wasserman E, Tam J, Mechoulam R, Zimmer A, Maor G, Bab I. CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol. Ann New York Acad Sci 2015;1335(1):110-119.

(65) Kogan NM, Melamed E, Wasserman E, Raphael B, Breuer A, Stok KS, et al. Cannabidiol, a major non-psychotropic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. J Bone Miner Res 2015;30(10):1905-1913.

(66) Mechoulam R. Looking ahead after 50 years of research on cannabinoids. Cannabinoids; 2014. p. 1-15.

(67) Mechoulam R, Hanuš LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 2014;15(11):757-764.

(68) Hanuš L, Shohami E, Bab I, Mechoulam R. N-Acyl amino acids and their impact on biological processes. Biofactors 2014;40(4):381-388.

(69) Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Δ9- tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Invest 2014;34(8):587-591.

(70) Kaminitz A, Barzilay R, Segal H, Taler M, Offen D, Gil-Ad I, et al. Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression. World J Biol Psychiatry 2014;15(1):76-82.

(71) Maslov LN, Lishmanov YB, Oeltgen P, Pei J-, Krylatov AV, Barzakh EI, et al. Effects of preconditioning on coronary perfusion in cardiac ischemia and reperfusion. Neurosci Behav Physiol 2013;43(9):1039-1048.

(72) Maslov LN, Headrick JP, Mechoulam R, Krylatov AV, Lishmanov AY, Barzakh EI, et al. The role of receptor transactivation in the cardioprotective effects of preconditioning and postconditioning. Neurosci Behav Physiol 2013;43(9):1015-1022.

(73) Mechoulam R, Shohami E. HU-211: A cannabinoid neuroprotective agent. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential; 2013. p. 389-398.

(74) Cohen-Yeshurun A, Willner D, Trembovler V, Alexandrovich A, Mechoulam R, Shohami E, et al. N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab 2013;33(8):1242-1250.

(75) Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013;75(2):323-333.

(76) Mechoulam R, Parker L. Towards a better cannabis drug. Br J Pharmacol 2013;170(7):1363-1364.

(77) Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47.

(78) Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology 2013;75:155-163.

(79) Limebeer CL, Rock EM, Mechoulam R, Parker LA. The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br J Pharmacol 2012;167(5):1126-1136.

(80) Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis 2012;3(6).

(81) Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BF, et al. Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol 2012;165(8):2425-2435.

(82) Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, et al. Cannabidiol, a nonpsychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT 1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012;165(8):2620-2634.

(83) Horváth B, Magid L, Mukhopadhyay P, Bátkai S, Rajesh M, Park O, et al. A new cannabinoid CB 2receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol 2012;165(8):2462-2478.

(84) Maslov LN, Headrick JP, Mechoulam R, Krylatov AV, Lishmanov AI, Barzakh EI, et al. [Role of receptor transactivation in the cardioprotective effects of preconditioning and postconditioning]. Ross Fiziol Zh Im I M Sechenova 2012;98(3):305-317.

(85) Mechoulam R. Cannabis - A valuable drug that deserves better treatment. Mayo Clin Proc 2012;87(2):107-109.

(86) Brown I, Wahle KWJ, Cascio MG, Smoum-Jaouni R, Mechoulam R, Pertwee RG, et al. Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukotrienes Essent Fatty Acids 2011;85(6):305-310.

(87) Bab I, Smoum R, Bradshaw H, Mechoulam R. Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family. Br J Pharmacol 2011;163(7):1441-1446.

(88) Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol 2011;163(7):1402-1410.

(89) Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gõmez-Cañas M, Valdeolivas S, et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011;163(7):1365-1378.

(90) Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. Erratum: The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat (Psychopharmacology DOI: 10.1007/s00213-007-0970-1). Psychopharmacology 2011;216(1):149.

(91) Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, et al. Interaction between non-psychotropic cannabinoids in marihuana: Effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 2011;215(3):505-512.

(92) Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to alzheimer's disease. Mol Pharmacol 2011;79(6):964-973.

(93) Lourbopoulos A, Grigoriadis N, Lagoudaki R, Touloumi O, Polyzoidou E, Mavromatis I, et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011;1390:126-141.

(94) Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 2011;50(10):1368-1381.

(95) Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011;50(2):193-211.

(96) Avraham Y, Grigoriadis NC, Poutahidis T, Vorobiev L, Magen I, Ilan Y, et al. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 2011;162(7):1650-1658.

(97) Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, Mechoulam R, Drucker-Colín R. Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci 2011;88(11-12):504-511.

(98) Ofek O, Attar-Namdar M, Kram V, Dvir-Ginzberg M, Mechoulam R, Zimmer A, et al. CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 2011;26(2):308-316.

(99) Mechoulam R, Hanus L. Other cannabinoids. Marijuana and Madness: Second Edition; 2011. p. 17-22.

(100) Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2011;203:75-104.

(101) Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley PJ, Mechoulam R, et al. N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab 2011;31(8):1768-1777.

(102) Rajesh M, Mukhopadhyay P, Btkai S, Patel V, Saito K, Matsumoto S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56(25):2115-2125.

(103) Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev 2010;62(4):588-631.

(104) Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, et al. Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A 2010;107(41):17710-17715.

(105) Pope C, Mechoulam R, Parsons L. Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology 2010;31(5):562-571.

(106) Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, et al. Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 2010;31(9):1584-1591.

(107) Mechoulam R. Endocannabinoids and psychiatric disorders: The road ahead. Rev Bras Psiquiatr 2010;32(SUPPL. 1):S5-S6.

(108) Hanuš LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem 2010;17(14):1341-1359.

(109) Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT 1A receptor activation. Br J Pharmacol 2010;159(4):950-957.

(110) Moussaieff A, Mechoulam R. Boswellia resin: From religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol 2009;61(10):1281-1293.

(111) Avraham Y, Grigoriadis NC, Magen I, Poutahidis T, Vorobiav L, Zolotarev O, et al. Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice. Br J Pharmacol 2009;158(3):896-906.

(112) Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51(3):528-534.

(113) Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia 2009;57(11):1154-1167.

(114) Avraham Y, Zolotarev O, Grigoriadis NC, Pautahidis T, Magen I, Vorobiav L, et al. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice (American Journal of Gastroenterology (2009) 103, (3047-3056) DOI: 10.1111/j.1572-0241.2008.02155.x). Am J Gastroenterol 2009;104(3):801.

(115) Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30(10):515-527.

(116) Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent. Behav Neurosci 2008;122(6):1378-1382.

(117) Patinkin D, Milman G, Breuer A, Fride E, Mechoulam R. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol 2008;595(1-3):1-6.

(118) Galanti G, Fisher T, Kventsel I, Shoham J, Gallily R, Mechoulam R, et al. Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 2008;47(6):1062-1070.

(119) Magen I, Avraham Y, Berry E, Mechoulam R. Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 2008;14(23):2362-2369.

(120) Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, et al. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 2008;22(8):3024-3034.

(121) Moussaieff A, Shein NA, Tsenter J, Grigoriadis S, Simeonidou C, Alexandrovich AG, et al. Incensole acetate: A novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab 2008;28(7):1341-1352.

(122) Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. A study investigating the acute dose-response effects of 13 mg and 17 mg Δ 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol 2008;22(4):441-451.

(123) Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, et al. The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008;283(19):13320-13324.

(124) Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev 2008;40(3):926-934.

(125) Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muñoz AL, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008;51(3):476-487.

(126) McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: Evidence for a site distinct from CB1 and CB 2. Mol Pharmacol 2008;73(2):441-450.

(127) Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 2008;196(3):389-395.

(128) Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2008;54(1):244-249.

(129) Avraham Y, Zolotarev O, Grigoriadis NC, Pautahidis T, Magen I, Vorobiav L, et al. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol 2008;103(12):3047-3056.

(130) Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. Brain imaging study of the acute effects of Δ9- tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology 2008;196(1):119-131.

(131) Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008;22(1):285-294.

(132) Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007;9(4):413-430.

(133) Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293(6):H3602-H3607.

(134) Moussaieff A, Shohami E, Kashman Y, Fride E, Schmitz ML, Renner F, et al. Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-κB activation. Mol Pharmacol 2007;72(6):1657-1664.

(135) Mechoulam R. Endocannabinoids: Functional roles and therapeutic opportunities. G Neuropsicofarmacol 2007;29(4):99-101.

(136) Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš LO. Cannabidiol - Recent advances. Chem Biodiversity 2007;4(8):1678-1692.

(137) Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007;26(4):843-851.

(138) Dagon Y, Avraham Y, Ilan Y, Mechoulam R, Berry EM. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J 2007;21(10):2431-2441.

(139) Kogan NM, Schlesinger M, Peters M, Marincheva G, Beeri R, Mechoulam R. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: A comparative in vivo study. J Pharmacol Exp Ther 2007;322(2):646-653.

(140) Dagon Y, Avraham Y, Link G, Zolotarev O, Mechoulam R, Berry EM. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis 2007;27(2):174-181.

(141) Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007;316(5830):1494-1497.

(142) García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007;1134(1):162-170.

(143) Hanuš L, Mechoulam R. Plant and brain Cannabinoids: The chemistry of major new players in physiology. Selected Topics in the Chemistry of Natural Products; 2007. p. 49-75.

(144) Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007;36(1):68-74.

(145) Kogan NM, Schlesinger M, Priel E, Rabinowitz R, Berenshtein E, Chevion M, et al. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther 2007;6(1):173-183.

(146) Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006;20(13):E1773-E1779.

(147) Mccarron RM, Chen Y, Tomori T, Strasser A, Mechoulam R, Shohami E, et al. Endothelial-mediated regulation of cerebral microcirculation. J Physiol Pharmacol 2006;57(SUPPL. 11):133-144.

(148) Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006;580(18):4337-4345.

(149) Kogan NM, Blázquez C, Álvarez L, Gallily R, Schlesinger M, Guzmán M, et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 2006;70(1):51-59.

(150) Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006;22(2):257-264.

(151) Mechoulam R, Berry EM, Avraham Y, Di Marzo V, Fride E. Endocannabinoids, feeding and suckling - From our perspective. Int J Obes 2006;30(SUPPL. 1):S24-S28.

(152) Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143-151.

(153) Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 2006;103(7):2428-2433.

(154) Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav 2006;87(1):66-71.

(155) Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006;103(3):696-701.

(156) Kogan NM, Mechoulam R. The chemistry of endocannabinoids. J Endocrinol Invest 2006;29(3 Suppl):3-14.

(157) Tam J, Ofek O, Fride E, Ledent C, Gabet Y, M̈uller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006;70(3):786-792.

(158) Avraham Y, Israeli E, Gabbay E, Okun A, Zolotarev O, Silberman I, et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2006;21(1):237-245.

(159) Mechoulam R, Deutsch DG. Toward an anandamide transporter. Proc Natl Acad Sci U S A 2005;102(49):17541-17542.

(160) Mechoulam R. Preface. Handb Exp Pharmacol 2005;168:VII-VIII.

(161) Mechoulam R. Plant cannabinoids: A neglected pharmacological treasure trove. Br J Pharmacol 2005;146(7):913-915.

(162) Moussaieff A, Fride E, Amar Z, Lev E, Steinberg D, Gallily R, et al. The Jerusalem Balsam: From the Franciscan Monastery in the old city of Jerusalem to Martindale 33. J Ethnopharmacol 2005;101(1-3):16-26.

(163) Unzicker C, Erberich H, Moldrich G, Woldt H, Bulla J, Mechoulam R, et al. Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: A neuroprotective substitution effect? Neurochem Res 2005;30(10):1305-1309.

(164) Fride E, Suris R, Weidenfeld J, Mechoulam R. Differential response to acute and repeated stress in cannabinoid CB 1 receptor knockout newborn and adult mice. Behav Pharmacol 2005;16(5-6):431-440.

(165) Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. J Cereb Blood Flow Metab 2005;25(4):477-484.

(166) Hanuš LO, Tchilibon S, Ponde DE, Breuer A, Fride E, Mechoulam R. Enantiomeric cannabidiol derivatives: Synthesis and binding to cannabinoid receptors. Org Biomol Chem 2005;3(6):1116-1123.

(167) Avraham Y, Menachem AB, Okun A, Zlotarav O, Abel N, Mechoulam R, et al. Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Res Bull 2005;65(2):117-123.

(168) Sarne Y, Mechoulam R. Cannabinoids: Between neuroprotection and neurotoxicity. Curr Drug Targets: CNS Neurol Disord 2005;4(6):677-684.

(169) Makriyannis A, Mechoulam R, Piomelli D. Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology 2005;48(8 SPEC. ISS.):1068-1071.

(170) Mechoulam R, Sumariwalla PF, Feldmann M, Gallily R. Cannabinoids in models of chronic inflammatory conditions. Phytochem Rev 2005;4(1):11-18.

(171) Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R. Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 2005;48(8 SPEC. ISS.):1139-1146.

(172) Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 2005;19(1-2):96-107.

(173) Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod 2005;11(1):21-28.

(174) Fride E, Feigin C, Ponde DE, Breuer A, Hanuš L, Arshavsky N, et al. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol 2004;506(2):179-188.

(175) Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al. Human brain endothelium: Coexpression and function of vanilloid and endocannabinoid receptors. Mol Brain Res 2004;132(1):87-92.

(176) Navab R, Aingorn H, Fallavollita L, Sallon S, Mechoulam R, Ginsburg I, et al. PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I. Inflammopharmacology 2004;12(4):373-389.

(177) Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R. Effect of low doses of Δ9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 2004;175(3):360-366.

(178) Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 2004;47(15):3800-3806.

(179) Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A Novel Synthetic, Nonpsychoactive Cannabinoid Acid (HU-320) with Antiinflammatory Properties in Murine Collagen-Induced Arthritis. Arthritis Rheum 2004;50(3):985-998.

(180) Mechoulam R. The promise of advances in the field of endocannabinoids. Neuro Endocrinol Lett 2004;25(1-2):11-12.

(181) Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 2004;174(2):254-259.

(182) Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 2004;171(2):156-161.

(183) Burstein S, Zurier RB, Sumariwalla PF, Feldmann M, Gallily R, Mechoulam R, et al. Pain reduction and lack of psychotropic effects with ajulemic acid: Comment on the article by Sumariwalla et al [4] (multiple letters). Arthritis Rheum 2004;50(12):4078-4079.

(184) Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol - Transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003;93(3):377-387.

(185) Mechoulam R, Lichtman AH. Stout guards of the central nervous system. Science 2003;302(5642).

(186) Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 2003;44(10):1767-1773.

(187) Hanuš L, Avraham Y, Ben-Shushan D, Zolotarev O, Berry EM, Mechoulam R. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 2003;983(1-2):144-151.

(188) Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 2003;93(2):66-70.

(189) Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: Effects of the cannabinoid HU-210. Stroke 2003;34(8):2000-2006.

(190) Mechoulam R, Parker L. Cannabis and alcohol - A close friendship. Trends Pharmacol Sci 2003;24(6):266-268.

(191) Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a "CB3" receptor. Eur J Pharmacol 2003;461(1):27-34.

(192) Parker LA, Mechoulam R. Cannabinoid Agonists and Antagonists Modulate Lithium-induced Conditioned Gaping in Rats. Integr Physiol Behav Sci 2003;38(2):133-145.

(193) Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 2003;166(2):156-162.

(194) Spatz M, McCarron RM, Shohami E, Panikashvili D, Chen Y, Golcch S, et al. Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG). Acta Neurochir Suppl 2003(86):271-275.

(195) Mechoulam R, Hanuš L. Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids 2002;121(1-2):35-43.

(196) Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 2002;42(11 SUPPL.):11S-19S.

(197) Laine K, Järvinen K, Mechoulam R, Breuer A, Järvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002;43(10):3216-3222.

(198) Ugdyzhekova DS, Krylatov AV, Bernatskaya NA, Maslov LN, Mechoulam R, Pertwee RG. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull Exp Biol Med 2002;133(2):125-126.

(199) Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R, et al. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: A possible mechanism. Bull Exp Biol Med 2002;133(2):122-124.

(200) Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54(2):161-202.

(201) Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002;13(5):567-570.

(202) Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 2002;513(2-3):294-298.

(203) Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukotrienes Essent Fatty Acids 2002;66(2-3):93-99.

(204) Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002;95(2):185-190.

(205) Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE 2002;2002(129).

(206) Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: Therapeutic implications. Trends Mol Med 2002;8(2):58-61.

(207) Krylatov AV, Bernatskaia NA, Maslov LN, Pertwee RG, Mechoulam R, Stefano GB, et al. Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors. Ross Fiziol Zh Im I M Sechenova 2002;88(5):560-567.

(208) Panikashvili D, Simeonidou C, Ben-Shabat S, Hanuš L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413(6855):527-531.

(209) Rubnov S, Kashman Y, Rabinowitz R, Schlesinger M, Mechoulam R. Suppressors of cancer cell proliferation from fig (Ficus carica) resin: Isolation and structure elucidation. J Nat Prod 2001;64(7):993-996.

(210) Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 2001;419(2-3):207-214.

(211) Mechoulam R, Fride E. Physiology: A hunger for cannabinoids. Nature 2001;410(6830):763-765.

(212) Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001;98(7):3662-3665.

(213) Mechoulam R, Hanuš L. The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manage 2001;6(2):67-73.

(214) Crozier Willi G, Berger A, Di Marzo V, Bisogno T, De Petrocellis L, Fride E, et al. Lipids in neural function: modulation of behavior by oral administration of endocannabinoids found in foods. Nestle Nutr Workshop Ser Clin Perform Programme 2001;5:169-184; discussion 185-187.

(215) Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845-852.

(216) Mechoulam R, Hanuš L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000;108(1-2):1-13.

(217) Tchilibon S, Mechoulam R. Synthesis of a primary metabolite of cannabidiol. Org Lett 2000;2(21):3301-3303.

(218) Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur J Pharmacol 2000;406(1):R5-R7.

(219) Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA, et al. Human brain capillary endothelium: 2-Arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 2000;87(4):323-327.

(220) Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97(17):9561-9566.

(221) Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000;392(3):147-156.

(222) Mechoulam R. Looking back at cannabis research. Curr Pharm Des 2000;6(13):1313-1322.

(223) Shohami E, Mechoulam R. Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. Drug Dev Res 2000;50(3-4):211-215.

(224) Ugdyzhekova DS, Davydova YG, Maimeskulova LA, Mechoulam R. Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. Bull Exp Biol Med 2000;130(11):1087-1089.

(225) Naveh N, Weissman C, Muchtar S, Benita S, Mechoulam R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefe's Arch Clin Exp Ophthalmol 2000;238(4):334-338.

(226) Mechoulam R. Recent advances in Cannabinoid research. Forsch Komplementarmed 1999;6(SUPPL. 3):16-20.

(227) Hanuš L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 1999;96(25):14228-14233.

(228) Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999;65(6-7):573-595.

(229) Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep 1999;16(2):131-143.

(230) Ginsburg I, Sadovnik M, Sallon S, Milo-Goldzweig I, Mechoulam R, Breuer A, et al. PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology 1999;7(1):47-62.

(231) Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, et al. Trick or treat from food endocannabinoids? [4] (multiple letters). Nature 1998;396(6712):636-637.

(232) Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 1998;362(1):R1-R3.

(233) Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998;359(1):1-18.

(234) Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee M-, Vogel Z, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998;353(1):23-31.

(235) Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998;59(2):347-352.

(236) Mechoulam R, Golan D. Comment on ‘Health aspects of cannabis: Revisited’ (Hollister). Int J Neuropsychopharmacol 1998;1(1):83-85.

(237) Mechoulam R, Hanuš L, Fride E. 5 Towards cannabinoid drugs - revisited. Prog Med Chem 1998;35(C):199-243.

(238) Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997;283(2):918-924.

(239) Bisogno T, Sepe N, De Petrocellis L, Mechoulam R, Di Marzo V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 1997;239(2):473-479.

(240) Rhee M-, Vogel Z, Barg J, Bayewitch M, Levy R, Hanuš L, et al. Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997;40(20):3228-3233.

(241) Sheskin T, Hanuš L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997;40(5):659-667.

(242) Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol 1997;72(2):169-177.

(243) Mechoulam R. Todd's achievement [6]. Nature 1997;386(6627):755.

(244) Mechoulam R, Fride E, Hanuš L, Sheskin T, Bisogno T, Marzo VD, et al. Anandamide may mediate sleep induction [6]. Nature 1997;389(6646):25-26.

(245) Shohami E, Weidenfeld J, Ovadia H, Vogel Z, Hanuš L, Fride E, et al. Endogenous and synthetic cannabinoids: Recent advances. CNS Drug Rev 1996;2(4):429-451.

(246) Fride E, Mechoulam R. Ontogenetic development of the response to anandamide and Δ9-tetrahydrocannabinol in mice. Dev Brain Res 1996;95(1):131-134.

(247) Bayewitch M, Rhee M-, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z. (-)-Δ9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 1996;271(17):9902-9905.

(248) Pop E, Soti F, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, et al. Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. Pharm Res 1996;13(3):469-475.

(249) Pop E, Liu ZZ, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, et al. Derivatives of dexanabinol. I. Water-soluble salts of glycinate esters. Pharm Res 1996;13(1):62-69.

(250) Fride E, Mechoulam R. Developmental aspects of anandamide: Ontogeny of response and prenatal exposure. Psychoneuroendocrinology 1996;21(2):157-172.

(251) Wilson Jr. RG, Tahir SK, Mechoulam R, Zimmerman S, Zimmerman AM. Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int 1996;20(2):147-157.

(252) Mechoulam R, Ben Shabat S, Hanuš L, Fride E, Bayewitch M, Vogel Z. Endogenous cannabinoid ligands. ADV EXP MED BIOL 1996;402:95-100.

(253) Mechoulam R, Ben Shabat S, Hanuš L, Fride E, Vogel Z, Bayewitch M, et al. Endogenous cannabinoid ligands - Chemical and biological studies. J LIPID MEDIATORS CELL SIGNAL 1996;14(1-3):45-49.

(254) Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, Heldman E, et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 1995;287(2):145-152.

(255) Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 1995;375(1-2):143-147.

(256) Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50(1):83-90.

(257) Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 1995;56(23-24):2097-2102.

(258) Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995;34(2):1725-175.

(259) Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995;34(2):175-180.

(260) Taura F, Morimoto S, Shoyama Y, Mechoulam R. First Direct Evidence for the Mechanism of Δ1-Tetrahydrocannabinolie Acid Biosynthesis. J Am Chem Soc 1995;117(38):9766-9767.

(261) Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol [3]. J Clin Psychiatry 1995;56(10):485-486.

(262) Fride E, Barg J, Levy R, Saya D, Heldman E, Mechoulam R, et al. Low doses of anandamides inhibit pharmacological effects of Δ9- tetrahydrocannabinol. J Pharmacol Exp Ther 1995;272(2):699-707.

(263) Glaser R, Adin I, Mechoulam R, Hanuš L. 2-Methyl- and 4-methyl-δ8-tetrahydrocannabinol: Correlation of spatial distinction with cannabinoid receptor binding. Heterocycles 1994;39(2):867-877.

(264) Martin BR, Childers S, Howlett A, Mechoulam R, Pertwee R. Cannabinoid receptors: Pharmacology, second messenger systems and endogenous ligands. NIDA RES MONOGR SER 1994(140):55-60.

(265) Vogel Z, Bayewitch M, Levy R, Matus-Leibovitch N, Hanus L, Ben-Shabat S, et al. Binding and functional studies with the peripheral and neuronal cannabinoid receptors. Regul Pept 1994;54(1):313-314.

(266) Mechoulam R, Hanuš L, Martin BR. Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994;48(8):1537-1544.

(267) Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci U S A 1994;91(16):7678-7682.

(268) Pertwee R, Griffin G, Hanuš L, Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol 1994;259(2):115-120.

(269) Abu-Lafi S, Sterin M, Levin S, Mechoulam R. Structural features affecting chiral discrimination of terpene derivatives, on a carbamated amylose stationary phase. J Chromatogr A 1994;664(2):159-167.

(270) Mechoulam R. Cannabis chemistry, biochemistry, toxicology and therapeutic applications. JPN J FORENSIC TOXICOL 1994;12(2):76-83.

(271) Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994;59(2):110-112.

(272) Järbe TUC, Mechoulam R, Zahalka J. Discriminative stimulus- and open-field effects of the enantiomers of 11-hydroxy-delta-8-tetrahydrocannabinol in pigeons and gerbils. Pharmacol Biochem Behav 1994;47(1):113-119.

(273) Mechoulam R, Vogel Z, Barg J. CNS Cannabinoid Receptors: Role and Therapeutic Implications for CNS Disorders. CNS Drugs 1994;2(4):255-260.

(274) Rodríguez De Fonseca F, Martín Calderón JL, Mechoulam R, Navarro M. Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxy-Δ8-tetrahydrocannabinol-dimethylheptyl-induced catalepsy in male rats. Neuroreport 1994;5(7):761-765.

(275) Guimarães FS, Aguiar JCd, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol Vasc Syst 1994;25(1):161-164.

(276) Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994;270(1):219-227.

(277) Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimetal autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994;28(3):209-214.

(278) Jarbe TUC, Hiltunen AJ, Mathis DA, Hanus L, Breuer A, Mechoulam R. Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; A comparison. J Pharmacol Exp Ther 1993;264(2):561-569.

(279) Nadler V, Mechoulam R, Sokolovsky M. The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-d-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 1993;162(1-2):43-45.

(280) Levin S, Abu-Lafi S, Zahalka J, Mechoulam R. Resolution of chiral cannabinoids on amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase: Effects of structural features and mobile phase additives. J Chromatogr A 1993;654(1):53-64.

(281) Nadler V, Mechoulam R, Sokolovsky M. Blockade of 45Ca2+ influx through the N-methyl-d-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 1993;622(1-2):79-85.

(282) Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231(2):313-314.

(283) Shohami E, Novikov M, Mechoulam R. A Nonpsychotropic Cannabinoid, HU-211, Has Cerebroprotective Effects After Closed Head Injury in the Rat. J Neurotrauma 1993;10(2):109-119.

(284) Hanuš L, Gopher A, Almog S, Mechoulam R. Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor. J Med Chem 1993;36(20):3032-3034.

(285) Martin BR, Cabral G, Childers SR, Deadwyler S, Mechoulam R, Reggio P. International Cannabis Research Society Meeting Summary, Keystone, CO (June 19-20, 1992). Drug Alcohol Depend 1993;31(3):219-227.

(286) Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase. J Neurochem 1993;61(1):352-355.

(287) Zlas J, Stark H, Seligman J, Levy R, Werker E, Breuer A, et al. Early medical use of cannabis [5]. Nature 1993;363(6426):215.

(288) Burstein SH, Audette CA, Doyle SA, Breuer A, Devane WA, Colodner S, et al. Synthetic Nonpsychotropic Cannabinoids with Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities. J Med Chem 1992;35(17):3135-3141.

(289) Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, Mechoulam R, et al. A Novel Probe for the Cannabinoid Receptor. J Med Chem 1992;35(11):2065-2069.

(290) Nathan I, Agam G, Mechoulam R, Dvilansky A, Livne AA. Effect of synthetic enantiomeric cannabinoids on platelet aggregation. Can J Physiol Pharmacol 1992;70(10):1305-1308.

(291) Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea‐pig small intestine. Br J Pharmacol 1992;105(4):980-984.

(292) Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-1949.

(293) Harvey DJ, Samara E, Mechoulam R. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1991;562(1-2):299-322.

(294) Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 1991;40(3):523-532.

(295) Mechoulam R, Breuer A, Feigenbaum JJ, Devane WA. Nonpsychotropic synthetic cannabinoids as therapeutic agents. Farmaco 1991;46(SUPPL. 1):267-276.

(296) Zimmerman AM, Titishov N, Mechoulam R, Zimmerman S. Effect of stereospecific cannabinoids on the immune system. ADV EXP MED BIOL 1991;288:71-80.

(297) Mechoulam R, Devane WA, Breuer A, Zahalka J. A random walk through a cannabis field. Pharmacol Biochem Behav 1991;40(3):461-464.

(298) Zeltser R, Seltzer Z, Eisen A, Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain 1991;47(1):95-103.

(299) Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40(3):471-478.

(300) Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica 1990;20(3):303-320.

(1) Razin S. The mycoplasma membrane. Organization of Prokaryotic Cell Membranes; 2018. p. 165-250.

(2) Razin S. Constructing a synthetic mycoplasma. In the Company of Microbes: Ten Years of Small Things Considered; 2016. p. 211-213.

(3) Razin S. Time-line of significant contributions to mycoplasmology. Biologicals 2010;38(2):191-192.

(4) Razin S, Hayflick L. Highlights of mycoplasma research-An historical perspective. Biologicals 2010;38(2):183-190.

(5) Razin S. Molecular biology and genomics of mollicutes. Bull Insect 2007;60(2):101-103.

(6) Razin S. Adherence of pathogenic mycoplasmas to host cells. Biosci Rep 1999;19(5):367-372.

(7) Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998;62(4):1094-1156.

(8) Razin S. Comparative genomics of mycoplasmas. Wien Klin Wochenschr 1997;109(14-15):551-556.

(9) Razin S. The minimal cellular genome of mycoplasma. Indian J Biochem Biophys 1997;34(1-2):124-130.

(10) Tully JG, Bove JM, Bradbury JM, Christiansen G, Kahane I, Kirkpatrick BC, et al. Revised minimum standards for description of new species of the class Mollicutes (division tenericutes). Int J Syst Bacteriol 1995;45(3):605-612.

(11) Razin S. DNA probes and PCR in diagnosis of mycoplasma infections. Mol Cell Probes 1994;8(6):497-511.

(12) Razin S. Mycoplasma membranes as models in membrane research. Subcell Biochem 1993;20:1-28.

(13) Razin S. Peculiar properties of mycoplasmas: The smallest self-replicating prokaryotes. FEMS Microbiol Lett 1992;100(1-3):423-431.

(14) Razin S, Jacobs E. Mycoplasma adhesion. J Gen Microbiol 1992;138(3):407-422.

(15) Yogev D, Sela S, Bercovier H, Razin S. Nucleotide sequence and codon usage of the elongation factor Tu(EF‐Tu) gene from Mycoplasma pneumoniae. Mol Microbiol 1990;4(8):1303-1310.

(16) Nur I, Reinhartz A, Hyman HC, Razin S, Herzberg M. Chemiprobe(TM), a nonradioactive system for labeling nucleic acid. Principles and applications. ANN BIOL CLIN 1989;47(10):601-606.

(17) Yogev D, Levisohn S, Razin S. Genetic and antigenic relatedness between Mycoplasma gallisepticum and Mycoplasma synoviae. Vet Microbiol 1989;19(1):75-84.

(18) Sela S, Yogev D, Razin S, Bercovier H. Duplication of the tuf gene: a new insight into the phylogeny of eubacteria. J Bacteriol 1989;171(1):581-584.

(19) Hyman HC, Levisohn S, Yogev D, Razin S. DNA probes for Mycoplasma gallisepticum and Mycoplasma synoviae: Application in experimentally infected chickens. Vet Microbiol 1989;20(4):323-337.

(20) Levisohn S, Hyman H, Razin S, Perelman D. The use of a specific dna probe for detection of mycoplasma gallisepticum in field outbreaks. Avian Pathol 1989;18(3):535-541.

(21) Gafny R, Hyman HC, Razin S, Glaser G. Promoters of Mycoplasma capricolum ribosomal RNA operons: Identical activities but different regulation in homologous and heterologous cells. Nucleic Acids Res 1988;16(1):61-76.

(22) Yogev D, Sela S, Bercovier H, Razin S. Elongation factor (EF-Tu) gene probe detects polymorphism in Mycoplasma strains. FEMS Microbiol Lett 1988;50(2-3):145-149.

(23) Hyman HC, Gafny R, Glaser G, Razin S. Promoter of the Mycoplasma pneumoniae rRNA operon. J Bacteriol 1988;170(7):3262-3268.

(24) Blanchard A, Razin S, Kenny GE, Barile MF. Characteristics of Ureaplasma urealyticum urease. J Bacteriol 1988;170(6):2692-2697.

(25) Yogev D, Halachmi D, Kenny GE, Razin S. Distinction of species and strains of mycoplasmas (Mollicutes) by genomic DNA fingerprints with an rRNA gene probe. J Clin Microbiol 1988;26(6):1198-1201.

(26) Yogev D, Tully JG, Rose DL, Razin S. Genetic and antigenic distinction of Mycoplasma pirum from other mycoplasmas with specialized tip structures. Int J Syst Bacteriol 1988;38(2):147-150.

(27) Yogev D, Levisohn S, Kleven SH, Halachmi D, Razin S. Ribosomal RNA gene probes to detect intraspecies heterogeneity in Mycoplasma gallisepticum and M. synoviae. Avian Dis 1988;32(2):220-231.

(28) Barile MF, Chandler DKF, Yoshida H, Grabowski MW, Razin S. Hamster challenge potency asay for evaluation of Mycoplasma pneumoniae vaccines. Infect Immun 1988;56(9):2450-2457.

(29) Barile MF, Chandler DKF, Yoshida H, Grabowski MW, Harasawa R, Razin S. Parameters of Mycoplasma pneumoniae infection in Syrian hamsters. Infect Immun 1988;56(9):2443-2449.

(30) Razin S. The Emmy Klieneberger-Nobel award lecture. Appealing attributes of mycoplasmas in cell biology research. Isr J Med Sci 1987;23(5):318-325.

(31) Razin S, Nur I, Glaser G. Spiroplasma plasmids. Isr J Med Sci 1987;23(6):678-682.

(32) Hyman HC, Yogev D, Razin S. DNA probes for detection and identification of Mycoplasma pneumoniae and Mycoplasma genitalium. J Clin Microbiol 1987;25(4):726-728.

(33) Hyman HC, Gafny R, Glaser G, Razin S. Transcription control elements of the Mycoplasma pneumoniae rRNA operon. Isr J Med Sci 1987;23(6):585-590.

(34) Razin S, Hyman HC, Nur I, Yogev D. DNA probes for detection and identification of mycoplasmas (Mollicutes). Isr J Med Sci 1987;23(6):735-741.

(35) Nur I, Glaser G, Razin S. Free and integrated plasmid DNA in spiroplasmas. Curr Microbiol 1986;14(3):169-176.

(36) Razin S, Yogev D. Genetic relatedness among ureaplasma urealyticum serotypes (Serovars). Pediatr Infect Dis J 1986;5(6):S300-S304.

(37) Yogev D, Razin S. Common deoxyribonucleic acid sequences in Mycoplasma genitalium and Mycoplasma pneumoniae genomes. Int J Syst Bacteriol 1986;36(3):426-430.

(38) Nur I, Bove JM, Saillard C, Rottem S, Whitcomb RM, Razin S. DNA probes in detection of spiroplasmas and mycoplasma-like organisms in plants and insects. FEMS Microbiol Lett 1986;35(2-3):157-162.

(39) Razin S. Molecular biology and genetics of mycoplasmas (Mollicutes). Microbiol Rev 1985;49(4):419-455.

(40) Davis PJ, Katznel A, Razin S, Rottem S. Spiroplasma membrane lipids. J Bacteriol 1985;161(1):118-122.

(41) Razin S, Amikam D, Glaser G. Mycoplasmal ribosomal RNA genes and their use as probes for detection and identification of Mollicutes. Isr J Med Sci 1984;20(9):758-761.

(42) Nur I, Razin S, Rottem S. Bilirubin incorporation into spiroplasma membranes and methylation of spiroplasmal DNA. Isr J Med Sci 1984;20(10):1019-1021.

(43) Glaser G, Amikam D, Razin S. Physical mapping of the ribosomal RNA genes of Mycoplasma capricolum. Nucleic Acids Res 1984;12(5):2421-2426.

(44) Razin S, Glaser G, Amikam D. Molecular and biological features of mollicutes (mycoplasmas). Ann Inst Pasteur Microbiol 1984;135(1):9-15.

(45) Amikam D, Glaser G, Razin S. Mycoplasmas (Mollicutes) have a low number of rRNA genes. J Bacteriol 1984;158(1):376-378.

(46) Harasawa R, Kotani H, Razin S, Koshimizu K. Genomic analysis of animal ureaplasmas by restriction endonucleases. Nippon Juigaku Zasshi 1984;46(5):737-740.

(47) Razin S, Gross M, Worer M, Pollack Y, Glaser G. Detection of mycoplasmas infecting cell cultures by DNA hybridization. In Vitro 1984;20(5):404-408.

(48) Chandler DKF, Izumikawa K, Razin S, Grabowski MW, Barile MF. Competitive inhibition and attachment assays in cell cultures to detect pathogenic binding components of mycoplasmas: A review. Ann Inst Pasteur Microbiol 1984;135(1):39-45.

(49) Bredt W, Feldner J, Kahane I, Razin S. Mycoplasma attachment to solid surfaces: A review. Yale J Biol Med 1983;56(5-6):653-656.

(50) Razin S, Barile MF, Harasawa R, Amikam D, Glaser G. Characterization of the mycoplasma genome. Yale J Biol Med 1983;56(5-6):357-366.

(51) Razin S, Harasawa R, Barile MF. Cleavage patterns of the mycoplasma chromosome, obtained by using restriction endonucleases, as indicators of genetic relatedness among strains. Int J Syst Bacteriol 1983;33(2):201-206.

(52) Razin S, Tully JG, Rose DL, Barile MF. DNA cleavage patterns as indicators of genotypic heterogeneity among strains of Acholeplasma and Mycoplasma species. J Gen Microbiol 1983;129(6):1935-1944.

(53) Amikam D, Razin S, Glaser G. Ribosomal RNA genes in mycoplasma. Nucleic Acids Res 1982;10(14):4215-4222.

(54) Razin S. Sterols in Mycoplasma Membranes. Curr Top Membr Transp 1982;17(C):183-205.

(55) Razin S, Rottem S. Preface. Curr Top Membr Transp 1982;17(C):17.

(56) Barile MF, Razin S, Tully JG. Preface. Rev Infect Dis 1982;4:S1.

(57) Efrati H, Oschry Y, Razin S, Eisenberg S. Preferential Uptake of Lipids by Mycoplasma Membranes from Human Plasma Low-Density Lipoproteins. Biochemistry 1982;21(25):6477-6482.

(58) Razin S, Efrati H, Kutner S, Rottem S. Cholesterol and phospholipid uptake by mycoplasmas. Rev Infect Dis 1982;4:S85-S92.

(59) Kahane I, Banai M, Razin S, Feldner J. Attachment of mycoplasmas to host cell membranes. Rev Infect Dis 1982;4:S185-S192.

(60) Chandler DKF, Razin S, Stephens EB, Harasawa R, Barile MF. Genomic and phenotypic analyses of Mycoplasma pneumoniae strains. Infect Immun 1982;38(2):604-609.

(61) Banai M, Razin S, Schuldiner S, Zilberstein D, Kahane I, Bredt W. Effects of ionophores and dicyclohexylcarbodiimide on Mycoplasma gallisepticum adherence to erythrocytes. Infect Immun 1982;38(1).

(62) Strehler BL, Abraham S, Bayreuther K, Bienenstock A, Binstock R, Birren J, et al. Hayflick-NIH settlement [3]. Science 1982;215(4530):240-242.

(63) Glaser G, Razin A, Razin S. Stable RNA synthesis and its control in mycoplasma capricolum. Nucleic Acids Res 1981;9(15):3641-3646.

(64) Efrati H, Rottem S, Razin S. Lipid and protein membrane components associated with cholesterol uptake by mycoplasmas. Biochim Biophys Acta Biomembr 1981;641(2):386-394.

(65) Razin S. Mycoplasmas: The smallest pathogenic procaryotes. Isr J Med Sci 1981;17(7):510-515.

(66) Feldner J, Bredt W, Razin S. Possible role of ATP and cyclic AMP in glass attachment of Mycoplasma pneumoniae. FEMS Microbiol Lett 1981;11(4):253-256.

(67) Feldner J, Bredt W, Razin S. Role of energy metabolism in Mycoplasma pneumoniae attachment to glass surfaces. Infect Immun 1981;31(1):107-113.

(68) Banai M, Kahane I, Feldner J, Razin S. Attachement of killed Mycoplasma gallisepticum cells and membrane to erythrocytes. Infect Immun 1981;34(2):422-427.

(69) Razin S, Kahane I, Banai M, Bredt W. Adhesion of mycoplasmas to eukaryotic cells. Ciba Found Symp 1981;80:98-118.

(70) Razin S, Banai M, Gamliel H, Polliack A, Bredt W, Kahane I. Scanning electron microscopy of mycoplasmas adhering to erythrocytes. Infect Immun 1980;30(2):538-546.

(71) Efrati H, Shinitzky M, Razin S. Effects of charged cholesteryl esters on mycoplasma growth. FEBS Lett 1980;122(1):59-63.

(72) Banai M, Razin S, Bredt W, Kahane I. Isolation of binding sites to glycophorin from Mycoplasma pneumoniae membranes. Infect Immun 1980;30(3):628-634.

(73) Razin S, Kutner S, Efrati H, Rottem S. Phospholipid and cholesterol uptake by mycoplasma cells and membranes. Biochim Biophys Acta Biomembr 1980;598(3):628-640.

(74) Razin A, Razin S. Methylated bases in mycoplasmal DNA. Nucleic Acids Res 1980;8(6):1383-1390.

(75) Amar A, Kahane I, Rottem S, Razin S. Binding of lectins to membranes of mycoplasmas from aging cultures. Microbios 1979;24(96):93-102.

(76) Amar A, Rottem S, Razin S. Is the vertical disposition of mycoplasma membrane proteins affected by membrane fluidity? Biochim Biophys Acta Biomembr 1979;552(3):457-467.

(77) Feldner J, Bredt W, Razin S. Adherence of Mycoplasma pneumoniae to glass surfaces. Infect Immun 1979;26(1):70-75.

(78) ROTTEM S, MARKOWITZ O, HASIN M, RAZIN S. Outer Membrane Proteins of Smooth and Rough Strains of Proteus mirabilis. Eur J Biochem 1979;97(1):141-146.

(79) Rottem S, Ulitzur S, Hasin M, Razin S. Susceptibility of phospholipids of Proteus mirabilis smooth and rough strains to endogenic phospholipase A activity. FEMS Microbiol Lett 1979;5(1):13-16.

(80) Kahane I, Gat O, Banai M, Bredt W, Razin S. Adherence of Mycoplasma gallisepticum to glass. J Gen Microbiol 1979;111(1):217-222.

(81) Razin S. Cholesterol uptake is dependent on membrane fluidity in mycoplasmas. Biochim Biophys Acta Biomembr 1978;513(3):401-404.

(82) Nixdorff k, Martin HH, Rottem S, Razin S. EPR studies on model membranes of phospholipid and outer membrane proteins of Proteus mirabilis. FEBS Lett 1978;94(2):298-300.

(83) Amar A, Rottem S, Razin S. Disposition of membrane proteins as affected by changes in the electrochemical gradient across mycoplasma membranes. Biochem Biophys Res Commun 1978;84(2):306-312.

(84) Razin S. The mycoplasmas. Microbiol Rev 1978;42(2):414-470.

(85) Razin S, Rottem S. Cholesterol in membranes: Studies with mycoplasmas. Trends Biochem Sci 1978;3(1):51-55.

(86) ROTTEM S, MARKOWITZ O, RAZIN S. Thermal Regulation of the Fatty Acid Composition of Lipopolysaccharides and Phospholipids of Proteus mirabilis. Eur J Biochem 1978;85(2):445-450.

(87) ROTTEM S, MARKOWITZ O, RAZIN S. Cerulenin‐Induced Changes in the Lipopolysaccharide Content and Phospholipid Composition of Proteus mirabilis. Eur J Biochem 1978;85(2):451-456.

(88) Kahane I, Razin S, Muhlrad A. Possible role of acetate kinase in atp generation in Mycoplasma hominis and Acholeplasma laidlawii. FEMS Microbiol Lett 1978;3(3):143-145.

(89) Banai M, Kahane I, Razin S, Bredt W. Adherence of Mycoplasma gallisepticum to human erythrocytes. Infect Immun 1978;21(2):365-372.

(90) Razin S, Masover GK, Palant M, Hayflick L. Morphology of Ureaplasma urealyticum (T mycoplasma) organisms and colonies. J Bacteriol 1977;130(1):464-471.

(91) Kahane I, Razin S. Cholesterol-phosphatidylcholine dispersions as donors of cholesterol to Mycoplasma membranes. Biochim Biophys Acta Biomembr 1977;471(1):32-38.

(92) Slutzky GM, Razin S, Kahane I, Eisenberg S. Cholesterol Transfer from Serum Lipoproteins to Mycoplasma Membranes. Biochemistry 1977;16(23):5158-5163.

(93) Kahane I, Greenstein S, Razin S. Carbohydrate content and enzymic activities in the membrane of Spiroplasma citri. J Gen Microbiol 1977;101(1):173-176.

(94) Masover GK, Razin S, Hayflick L. Effects of carbon dioxide, urea, and ammonia on growth of Ureaplasma urealyticum (T strain mycoplasma). J Bacteriol 1977;130(1):292-296.

(95) Masover GK, Razin S, Hayflick L. Localization of enzymes in Ureaplasma urealyticum (T strain mycoplasma). J Bacteriol 1977;130(1):297-302.

(96) Slutzky GM, Razin S, Kahane I, Eisenberg S. Inhibition of mycoplasma growth by human very low-density lipoproteins. FEMS Microbiol Lett 1977;2(4):185-187.

(97) Razin S, Pfendt EA, Matsumura T, Hayflick L. Comparison by autoradiography of macromolecular biosynthesis in "young" and "old" human diploid fibroblast cultures. A brief note. Mech Ageing Dev 1977;6(C):379-384.

(98) Larraga V, Razin S. Reduced nicotinamide adenine dinucleotide oxidase activity in membranes and cytoplasm of Acholeplasma laidlawii and Mycoplasma mycoides subsp. capri. J Bacteriol 1976;128(3):827-833.

(99) Hasin M, Razin S, Rottem S. The outer membrane of Proteus mirabilis III. Specific labeling and enzymic hydrolysis of the protein and phospholipid components of the outer and cytoplasmic membranes. Biochim Biophys Acta Biomembr 1976;433(2):229-239.

(100) Razin S, Marknowitz O, Hasin M, Rottem S. The outer membrane of Proteus mirabilis IV. Solubilization and fractionation of the outer and cytoplasmic membrane components. Biochim Biophys Acta Biomembr 1976;433(2):240-251.

(101) Amar A, Rottem S, Kahane I, Razin S. Characterization of the mycoplasma membrane proteins. VI. Composition and disposition of proteins in membranes from aging Mycoplasma hominis cultures. Biochim Biophys Acta Biomembr 1976;426(2):258-270.

(102) Slutzky GM, Razin S, Kahane I, Eisenberg S. Serum lipoproteins as cholesterol donors to mycoplasma membranes. Biochem Biophys Res Commun 1976;68(2):529-536.

(103) Romano N, Rottem S, Razin S. Biosynthesis of saturated and unsaturated fatty acids by a T strain mycoplasma (Ureaplasma). J Bacteriol 1976;128(1):170-173.

(104) Razin S. Cholesterol incorporation into bacterial membranes. J Bacteriol 1975;124(1):570-572.

(105) Amar A, Rottem S, Kahane I, Razin S. Proceedings: Effects of the culture age on the composition and properties of Mycoplasma membranes. Isr J Med Sci 1975;11(11):1194.

(106) Rottem S, Hasin M, Razin S. The outer membrane of Proteus mirabilis II. The extractable lipid fraction and electron-paramagnetic resonance analysis of the outer and cytoplasmic membranes. Biochim Biophys Acta Biomembr 1975;375(3):395-405.

(107) Hasin M, Rottem S, Razin S. The outer membrane of Proteus mirabilis I. Isolation and characterization of the outer and cytoplasmic membrane fractions. Biochim Biophys Acta Biomembr 1975;375(3):381-394.

(108) Ne'Eman Z, Razin S. Characterization of the mycoplasma membrane proteins. V. Release and localization of membrane-bound enzymes in Acholeplasma laidlawii. Biochim Biophys Acta Biomembr 1975;375(1):54-68.

(109) Raccach M, Rottem S, Razin S. Survival of frozen mycoplasmas. Appl Microbiol 1975;30(2):167-171.

(110) Razin S. Correlation of cholesterol to phospholipid content in membranes of growing mycoplasmas. FEBS Lett 1974;47(1):81-85.

(111) Gershfeld NL, Wormser M, Razin S. Cholesterol in mycoplasma membranes. I. Kinetics and equilibrium studies of cholesterol uptake by the cell membrane of Acholeplasma laidlawii. Biochim Biophys Acta Biomembr 1974;352(3):371-384.

(112) Razin S, Wormser M, Gershfeld NL. Cholesterol in mytoplasma membranes. II Components of Acholeplasma laidlawii cell membranes responsible for cholesterol binding. Biochim Biophys Acta Biomembr 1974;352(3):385-396.

(113) Amar A, Rottem S, Razin S. Characterization of the mycoplasma membrane proteins IV. Disposition of proteins in the membrane. Biochim Biophys Acta Biomembr 1974;352(2):228-244.

(114) Razin S. Reconstitution of mycoplasma membranes. J Supramol Struct Cell Biochem 1974;2(5-6):670-681.

(115) Razin S, Rottem S. [42] Isolation, Solubilization, and Reconstitution of Mycoplasma Membranes. Methods Enzymol 1974;32(C):459-468.

(116) Razin S, Hasin M, Ne'eman Z, Rottem S. Isolation, chemical composition, and ultrastructural features of the cell membrane of the mycoplasma like organism Spiroplasma citri. J Bacteriol 1973;116(3):1421-1435.

(117) Rottem S, Hasin M, Razin S. Differences in susceptibility to phospholipase C of free and membrane-bound phospholipids of Mycoplasma hominis. Biochim Biophys Acta Biomembr 1973;323(4):520-531.

(118) Rottem S, Yashouv J, Ne'eman Z, Razin S. Cholesterol in mycoplasma membranes. Composition, ultrastructure and biological properties of membranes from Mycoplasma mycoides var. capri cells adapted to grow with low cholesterol concentrations. Biochim Biophys Acta Biomembr 1973;323(4):495-508.

(119) Rottem S, Cirillo VP, De Kruyff B, Shinitzky M, Razin S. Cholesterol in mycoplasm membranes. Correlation of enzymic and transport activities with physical state of lipids in membranes of Mycoplasma mycoides var. capri adapted to grow with low cholesterol concentrations. Biochim Biophys Acta Biomembr 1973;323(4):509-519.

(120) Rottem S, Hasin M, Razin S. Binding of proteins to mycoplasma membranes. Biochim Biophys Acta Biomembr 1973;298(4):876-886.

(121) Rottem S, Razin S. Membrane lipids of Mycoplasma hominis. J Bacteriol 1973;113(2):565-571.

(122) Rottem S, Muhsam-Peled O, Razin S. Acyl carrier protein in mycoplasmas. J Bacteriol 1973;113(2):586-591.

(123) Kahane I, Ne'eman Z, Razin S. Divalent cations in native and reaggregated mycoplasma membranes. J Bacteriol 1973;113(2):666-671.

(124) Razin S. Physiology of Mycoplasmas. Adv Microb Physiol 1973;10(C):1-80.

(125) Stone SS, Razin S. Immunoelectrophoretic analysis of Mycoplasma mycoides var. mycoides. Infect Immun 1973;7(6):922-930.

(126) Levisohn S, Razin S. Isolation, ultrastructure and antigenicity of Mycoplasma gallisepticum membranes. J Hyg 1973;71(4):725-737.

(127) Cirillo VP, Razin S. Distribution of a phosphoenolypyruvate-dependent sugar phosphotransferase system in mycoplasms. J Bacteriol 1973;113(1):212-217.

(128) Razin S, Rottem S, Hasin M, Gershfeld NL. BINDING OF EXOGENOUS PROTEINS AND LIPIDS TO MYCOPLASMA MEMBRANES. Ann New York Acad Sci 1973;225(1):28-37.

(129) Rottem S, Razin S. Isolation of mycoplasma membranes by digitonin. J Bacteriol 1972;110(2):699-705.

(130) Razin S. Reconstitution of biological membranes. Biochim Biophys Acta Rev Biomembr 1972;265(2):241-296.

(131) Ne'eman Z, Kahane I, Kovartovsky J, Razin S. Characterization of the myoplasma membrane proteins. III. Gel filtration and immunological characterization of Acholeplasma laidlawii membrane proteins. Biochim Biophys Acta Biomembr 1972;266(1):255-268.

(132) Bredt W, Maniloff J, Das J, Quinlan D, Biberfeld G, Biberfeld P, et al. International mycoplasma symposium 6/7th September 1971 in Mainz Summaries of the papers. Med Microbiol Immunol 1972;157(2):169-180.

(133) Kahane I, Razin S. Characterization of the mycoplasma membrane proteins I. Reaggregation of solubilized membrane proteins of Acholeplasma laidlawii. Biochim Biophys Acta Biomembr 1971;249(1):159-168.

(134) Ne'eman Z, Kahane I, Razin S. Characterization of the mycoplasma membrane proteins II. Solubilization and enzymic activities of Acholeplasma laidlawii membrane proteins. Biochim Biophys Acta Biomembr 1971;249(1):169-176.

(135) Brunner H, Razin S, Kalica AR, Chanock RM. Lysis and death of Mycoplasma pneumoniae by antibody and complement. J Immunol 1971;106(4):907-916.

(136) Cole RM, Popkin TJ, Prescott B, Chanock RM, Razin S. Electron microscopy of solubilized Acholeplasma laidlawii membrane proteins reaggregated with Mycoplasma pneumoniae glycolipids. Biochim Biophys Acta Biomembr 1971;233(1):76-83.

(137) Razin S, Chanock RM, Graf L, Rapport MM. Immunogenicity of Cytolipin H Aggregated with Acholeplasma laidlawii Membrane Proteins. Proc Soc Exp Biol Med 1971;138(2):404-407.

(138) Kahane I, Razin S. pH-dependent changes in density of plasma membranes of growing Mycoplasma laidlawii cells. FEBS Lett 1970;10(4):261-264.

(139) Tillack TW, Carter R, Razin S. Native and reformed Mycoplasma laidlawii membranes compared by freeze-etching. Biochim Biophys Acta Biomembr 1970;219(1):123-130.

(140) Tully JG, Razin S. Acholeplasma axanthum, sp. n.: a new sterol-nonrequiring member of the Mycoplasmatales. J Bacteriol 1970;103(3):751-754.

(141) Razin S, Valdesuso J, Purcell RH, Chanock RM. Electrophoretic analysis of cell proteins of T-strain mycoplasmas isolated from man. J Bacteriol 1970;103(3):702-706.

(142) Razin S, Tully JG. Cholesterol requirement of mycoplasmas. J Bacteriol 1970;102(2):306-310.

(143) Tully JG, Barile MF, Del Giudice RA, Carski TR, Armstrong D, Razin S. Proposal for classifying strain PG-24 and related canine mycoplasmas as Mycoplasma edwardii sp. n. J Bacteriol 1970;101(2):346-349.

(144) Razin S, Prescott B, Chanock RM. Immunogenicity of Mycoplasma pneumoniae glycolipids: a novel approach to the production of antisera to membrane lipids. Proc Natl Acad Sci U S A 1970;67(2):590-597.

(145) Razin S, Kahane I. Hybridization of solubilized membrane components from different mycoplasma species by reaggregation. Nature 1969;223(5208):863-864.

(146) Razin S, Ne'eman Z, Ohad I. Selective reaggregation of solubilized mycoplasma-membrane proteins and the kinetics of membrane reformation. Biochim Biophys Acta Biomembr 1969;193(2):277-293.

(147) Kahane I, Razin S. Immunological analysis of Mycoplasma membranes. J Bacteriol 1969;100(1):187-194.

(148) Razin S. Organization of protein and lipid in the mycoplasma membrane. J Gen Microbiol 1969;57(3):8-9.

(149) Kahane I, Razin S. Synthesis and turnover of membrane protein and lipid in Mycoplasma laidlawii. Biochim Biophys Acta Biomembr 1969;183(1):79-89.

(150) Razin S. Structure and function in mycoplasma. Annu Rev Microbiol 1969;23:317-356.

(151) Razin S, Barash V. Solubilization of mycoplasma membranes by the nonionic detergent Triton X-100. FEBS Lett 1969;3(3):217-220.

(152) Razin S, Shafer Z. Incorporation of cholesterol by membranes of bacterial L-phase variants with an appendix on the determination of the L-phase parentage by the electrophoretic patterns of cell proteins. J Gen Microbiol 1969;58(3):327-339.

(153) Tully JG, Razin S. Characteristics of a new sterol-nonrequiring Mycoplasma. J Bacteriol 1969;98(3):970-978.

(154) Rottem S, Razin S. Sugar transport in Mycoplasma gallisepticum. J Bacteriol 1969;97(2):787-792.

(155) Argaman M, Razin S. Antigenic properties of mycoplasma organisms and membranes. J Gen Microbiol 1969;55(1):45-58.

(156) Sacks TG, Haas H, Razin S. Polyacrylamide-gel electrophoresis of cell proteins of Enterobacteriaceae. A possible taxonomic aid. Isr J Med Sci 1969;5(1):49-55.

(157) Razin S, Gottfried L, Rottem S. Amino acid transport in Mycoplasma. J Bacteriol 1968;95(5):1685-1691.

(158) Razin S. Mycoplasma taxonomy studiedy electrophoresis of cell proteins. J Bacteriol 1968;96(3):687-694.

(159) Razin S, Boschwitz C. The membrane of the Streptobacillus moniliformis L-phase. J Gen Microbiol 1968;54(1):21-32.

(160) Tully JG, Razin S. Physiological and serological comparisons among strains of Mycoplasma granularum and Mycoplasma laidlawii. J Bacteriol 1968;95(5):1504-1512.

(161) Rottem S, Gottfried L, Razin S. Carotenoids as protectors against photodynamic inactivation of the adenosine triphosphatase of Mycoplasma laidlawii membranes. Biochem J 1968;109(4):707-708.

(162) Rottem S, Stein O, Razin S. Reassembly of Mycoplasma membranes disaggregated by detergents. Arch Biochem Biophys 1968;125(1):46-56.

(163) Razin S. THE CELL MEMBRANE OF MYCOPLASMA. Ann New York Acad Sci 1967;143(1):115-129.

(164) Razin S, Rottem S. Identification of Mycoplasma and other microorganisms by polyacrylamide-gel electrophoresis of cell proteins. J Bacteriol 1967;94(6):1807-1810.

(165) Rottem S, Razin S. Electrophoretic patterns of membrane proteins of Mycoplasma. J Bacteriol 1967;94(2):359-364.

(166) Razin S, Rottem S. Role of carotenoids and cholesterol in the growth of Mycoplasma laidlawii. J Bacteriol 1967;93(3):1181-1182.

(167) Razin S, Cosenza BJ, Tourtellotte ME. FILAMENTOUS GROWTH OF MYCOPLASMA. Ann New York Acad Sci 1967;143(1):66-72.

(168) Rodwell AW, Razin S, Rottem S, Argaman M. Association of protein and lipid in Mycoplasma laidlawii membranes disaggregated by detergents. Arch Biochem Biophys 1967;122(3):621-628.

(169) Edward DGF, Freundt EA, Chanock RM, Fabricant J, Hayflick L, Lemcke RM, et al. Recommendations on nomenclature of the order mycoplasmatales. Science 1967;155(3770):1694-1696.

(170) Rottem S, Razin S. Adenosine triphosphatase activity of mycoplasma membranes. J Bacteriol 1966;92(3):714-722.

(171) Razin S, Cosenza BJ. Growth phases of Mycoplasma in liquid media observed with phase-contrast microscope. J Bacteriol 1966;91(2):858-869.

(172) Razin S, Cosenza BJ, Tourtellotte ME. Variations in Mycoplasma morphology induced by long-chain fatty acids. J Gen Microbiol 1966;42(1):139-145.

(173) Razin S, Tourtellotte ME, McElhaney RN, Pollack JD. Influence of lipid components of Mycoplasma laidlawii membranes on osmotic fragility of cells. J Bacteriol 1965;91(2):609-616.


(175) Razin S, Cleverdon RC. Carotenoids and cholesterol in membranes of Mycoplasma laidlawii. J Gen Microbiol 1965;41(3):409-415.

(176) Razin S, Morowitz HJ, Terry TM. Membrane subunits of Mycoplasma laidlawii and their assembly to membranelike structures. Proc Natl Acad Sci U S A 1965;54(1):219-225.

(177) Pollack JD, Razin S, Pollack ME, Cleverdon RC. Fractionation of Mycoplasma cells for enzyme localization. Life Sci 1965;4(9):973-977.


(179) ROTTEM S, RAZIN S. LIPASE ACTIVITY OF MYCOPLASMA. J Gen Microbiol 1964;37:123-134.

(180) Razin S, Michmann J, Shimshoni Z. The Occurrence of Mycoplasma (Pleuropneumonia-like Organisms, PPLO) in the Oral Cavity of Dentulous and Edentulous Subjects. J Dent Res 1964;43(3):402-405.


(182) Razin S. Binding of nystatin by mycoplasma (pleuropneumonia-like organisms). BBA - Biochimica et Biophysica Acta 1963;78(4):771-773.

(183) RAZIN S. OSMOTIC LYSIS OF MYCOPLASMA. J Gen Microbiol 1963;33:471-475.


(185) RAZIN S, COHEN A. Nutritional requirements and metabolism of Mycoplasma laidlawii. J Gen Microbiol 1963;30:141-154.

(186) RAZIN S, ARGAMAN M. Lysis of Mycoplasma, bacterial protoplasts, spheroplasts and L-forms by various agents. J Gen Microbiol 1963;30:155-172.


(188) Razin S, Argaman M. Susceptibility of mycoplasma (pleuropneumonia-like organisms) and bacterial protoplasts to lysis by various agents [45]. Nature 1962;193(4814):502-503.

(189) Bercovici B, Persky S, Rozansky R, Razin S. Mycoplasma (pleuropneumonia-like organisms) in vaginitis. Am J Obstet Gynecol 1962;84(5):687-691.

(190) RAZIN S, ARGAMAN M. Comparative studies of Mycoplasma (PPLO), bacterial protoplasts and L-forms. Harefuah 1962;62:259-263.

(191) RAZIN S. Nucleic acid precursor requirements of Mycoplasma laidlawii. J Gen Microbiol 1962;28:243-250.

(192) RAZIN S, KNIGHT BC. The effects of ribonucleic acid and deoxyribonucleic acid on the growth of Myeoplasma. J Gen Microbiol 1960;22:504-519.

(193) BACHRACH U, PERSKY S, RAZIN S. Metabolism of amines. 2. The oxidation of natural polyamines by Myocobacterium smegmatis. Biochem J 1960;76:306-310.

(194) Razin S, Rozansky R. Mechanism of the antibacterial action of spermine. Arch Biochem Biophys 1959;81(1):36-54.

(195) RAZIN S, GERY I, BACHRACH U. The degradation of natural polyamines and diamines by bacteria. Biochem J 1959;71(3):551-558.

(196) Razin S, Bachrach U, Gery I. Formation of β-alanine from spermine and spermidine by Pseudomonas aeruginosa [14]. Nature 1958;181(4610):700-701.

(197) Razin S, Cohen A, Rozansky R. Antimycotic Effect of Spermine. Proc Soc Exp Biol Med 1958;99(2):459-462.

(198) Razin S, Rozansky R. The responsibility of spermine for the antibacterial action of human semen. J Lab Clin Med 1957;49(6):877-881.

(199) GROSSOWICZ N, RAZIN S, ROZANSKY R. Factors influencing the antibacterial action of spermine and spermidine on Staphylococcus aureus. J Gen Microbiol 1955;13(3):436-441.